High Prevalence of Anti-GD2 Immunotherapy-Associated Ocular Adverse Effects Following Allogeneic HCT for Neuroblastoma
Authors:
- Tomoi FurukawaTFTomoi Furukawa
- Ryo AkazawaRARyo Akazawa
- Katsutsugu UmedaKUKatsutsugu Umeda
- Shuro NishioSNShuro Nishio
- Hirohito KubotaHKHirohito Kubota
- Satoshi SaidaSSSatoshi Saida
- Itaru KatoIKItaru Kato
- Naoko Ueda-ArakawaNUNaoko Ueda-Arakawa
- Tatsuya OkamotoTOTatsuya Okamoto
- Kimiyoshi SakaguchiKSKimiyoshi Sakaguchi
- Junko TakitaJTJunko Takita
- 29 September 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (8) , 385-387
Abstract
Background: GD2 is also expressed in normal ocular structures; however, much remains unknown about the risk factors for ocular adverse effects AEs following anti-GD2 immunotherapy remain unknown. Observations: We retrospectively analyzed risk factors for ocular AEs in 9 high-risk neuroblastoma patients. One of the 6 patients who underwent autologous hematopoietic cell transplantation (HCT) alone developed ocular AEs, whereas all 3 patients undergoing tandem autologous-allogeneic HCT did. Other variables, including age, history of anti-GD2 immunotherapy, and preimmunotherapy disease status, showed no significant association with ocular AEs. Conclusions: Allogeneic HCT before anti-GD2 immunotherapy may be a risk factor for ocular AEs.Keywords
This publication has 13 references indexed in Scilit:
- Impact of Vision Impairment and Ocular Morbidity and Their Treatment on Quality of Life in ChildrenOphthalmology, 2023
- Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2022
- G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatmentJournal for ImmunoTherapy of Cancer, 2021
- Killer‐cell immunoglobulin‐like receptor ligand mismatch cord blood transplantation in high‐risk neuroblastomaPediatrics International, 2019
- Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trialThe Lancet Oncology, 2018
- Ocular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322AJournal of American Association for Pediatric Ophthalmology and Strabismus, 2015
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaNew England Journal of Medicine, 2010
- Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastomaCancer Immunology, Immunotherapy, 2002
- Phase I Study of Chimeric Human/Murine Anti–Ganglioside GD2Monoclonal Antibody (ch14.18) With Granulocyte-Macrophage Colony-Stimulating Factor in Children With Neuroblastoma Immediately After Hematopoietic Stem-Cell Transplantation: A Children’s Cancer Group StudyJournal of Clinical Oncology, 2000
- Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibodyPain, 1997